Record details

Living Modified Organism identity

The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name

VECTORMUNE® HVT-NDV + Rispens

Transformation event

HVT-F/NDV

Developer(s)

Record #114743

Dr Alexis Henry Gaetan Goux

President of CIBio

Ceva Saude Animal Ltda (CEVA)

Rua Manuel Joaquim Filho, 303 Pulinia - SP
Sao Paulo, Brazil
13140-000

Sao Paulo

Brazil

Phone:	+551938337700
Email:	alexisgoux@ceva.com

Description

Vectormune HVT-NDV & Rispens is vaccine against Newcastle disease (ND) and Marek's Disease (MD; Rispens). The vaccine contains modified Turkey Herpesvirus (Marek's disease vaccine; serotype 3), expressing fusion protein from Newcastle disease virus, and an attenuated strain of Gallid alphaherpesvirus 2 (Marek's Disease virus) serotype 1.

Note: Only the Turkey Herpesvirus was modified.

Recipient Organism or Parental Organisms

The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.

Record #105225

Meleagrid herpesvirus 1 - Turkey Herpesvirus

Record #48969

Gallid herpesvirus 2

Point of collection or acquisition of the recipient organism

Turkey Herpesvirus: wild-type; strain FC126

Characteristics of the transformation process

Vector

p45/46PecF

Techniques used for the modification

Cell transfection and recombination

Genetic elements construct

CMV Early Enhancer

#114749

0.28 Kb

Beta-actin gene promoter

#105217

0.27 Kb

Fusion protein gene

#105090

1.90 Kb

SV40 poly-adenylation signal

#114748

0.12 Kb

Further details

Notes regarding the genetic elements introduced or modified in this LMO

The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.

During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.

The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2). A second attenuated strain of the virulent Merek's Disease virus has been included to convey broader immunity against Merek's disease virus.

Note:
The expression of Protein F was confirmed using Southern blotting.

LMO characteristics

Modified traits

Production of medical or pharmaceutical compounds (human or animal)
- Vaccines

Common use(s)

Vaccine

Additional Information

Other relevant website address or attached documents

Vectormune® ND + Rispens

US 6,866,852 B2 Patent.pdf

Advancement in Vaccination Against Newcastle Disease - Recombinant HVT NDV.pdf